Protocol for rheumatoid arthritis complicated with cardiovascular damage treated with Guanxining tablet with a randomized controlled trial

ABSTRACT:

Background

Cardiovascular disease (CVD) is the main cause of death in patients with rheumatoid arthritis (RA). Apart from traditional cardiovascular risk factors, immune dysfunction and chronic inflammation of RA are also risk factors for complex cardiovascular damage. Although methotrexate (MTX) is beneficial to CVD in RA patients by inhibiting inflammation, its adverse effects limit its clinical application. Therefore, it is essential to seek safer and more effective drugs.

Objective

We aimed to assess the efficacy of Guanxining Tablet (GXNT) for rheumatoid arthritis complicated with cardiovascular damage.

Methods

We will conduct a prospective single-center randomized trial. We will randomly divide 56 eligible patients into two groups. The treatment group will

SUBMITTER: Yu K 

PROVIDER: S-EPMC10474432 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature